• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Aspirin negatively interacts with PCa hormone therapy

Article

Baby aspirin appeared to interfere with the ability to deliver a full course of hormone therapy in 206 men with localized but high- or intermediate-risk prostate cancers who were enrolled in a study comparing radiation therapy alone with radiation therapy plus hormone therapy. In a letter to the editor of the New England Journal of Medicine (2007; 357:2737-8), Anthony V. D’Amico, MD, PhD, and Philip W. Kantoff, MD, of the Dana–Farber Cancer Institute, Boston, discussed the effects of low-dose aspirin on liver function tests.

Baby aspirin appeared to interfere with the ability to deliver a full course of hormone therapy in 206 men with localized but high- or intermediate-risk prostate cancers who were enrolled in a study comparing radiation therapy alone with radiation therapy plus hormone therapy. In a letter to the editor of the New England Journal of Medicine (2007; 357:2737-8), Anthony V. D’Amico, MD, PhD, and Philip W. Kantoff, MD, of the Dana–Farber Cancer Institute, Boston, discussed the effects of low-dose aspirin on liver function tests.

Hormone therapy consisted of 6 months of a luteinizing hormone–releasing hormone agonist and the antiandrogen flutamide (Eulexin). A logistic-regression multivariable analysis was used to assess whether an association existed between commonly used drugs (aspirin or atorvastatin [Lipitor]) and the discontinuation of flutamide due to elevated values on liver function tests. The use of baby aspirin was significantly associated with abnormal liver function tests (p=.02), whereas the use of atorvastatin was not (p=.13).

Flutamide was prematurely discontinued in 37% of aspirin users compared with 16% of nonusers because of abnormal liver function tests. Moreover, after a median follow-up of 7.6 years and adjustment for known prognostic factors and interactions, and with men who completed 6 months of hormone therapy with both the LHRH agonist and flutamide as the comparison group, the risk of death was 3.5 times as high among men who completed 6 months of the LHRH agonist but discontinued flutamide early (p=.04) and 6.1 times as high among men treated with radiation therapy alone (p<.001). These data show that a commonly used drug can alter the tolerability of anticancer therapy.

Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
David Gilbert answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.